Stock Research for IPCI

IPCI

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

IPCI Stock Chart & Research Data

The IPCI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IPCI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


IPCI Due diligence Resources & Stock Charts

The IPCI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IPCI Detailed Price Forecast - CNN Money CNN View IPCI Detailed Summary - Google Finance
Yahoo View IPCI Detailed Summary - Yahoo! Finance Zacks View IPCI Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View IPCI Trends & Analysis - Trade-Ideas Barrons View IPCI Major Holders - Barrons
NASDAQ View IPCI Call Transcripts - NASDAQ Seeking View IPCI Breaking News & Analysis - Seeking Alpha
Spotlight View IPCI Annual Report - CompanySpotlight.com OTC Report View IPCI OTC Short Report - OTCShortReport.com
TradeKing View IPCI Fundamentals - TradeKing Charts View IPCI SEC Filings - Bar Chart
WSJ View Historical Prices for IPCI - The WSJ Morningstar View Performance/Total Return for IPCI - Morningstar
MarketWatch View the Analyst Estimates for IPCI - MarketWatch CNBC View the Earnings History for IPCI - CNBC
StockMarketWatch View the IPCI Earnings - StockMarketWatch MacroAxis View IPCI Buy or Sell Recommendations - MacroAxis
Bullish View the IPCI Bullish Patterns - American Bulls Short Pains View IPCI Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View IPCI Stock Mentions - StockTwits PennyStocks View IPCI Stock Mentions - PennyStockTweets
Twitter View IPCI Stock Mentions - Twitter Invest Hub View IPCI Investment Forum News - Investor Hub
Yahoo View IPCI Stock Mentions - Yahoo! Message Board Seeking Alpha View IPCI Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for IPCI - SECform4.com Insider Cow View Insider Transactions for IPCI - Insider Cow
CNBC View IPCI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IPCI - OTC Markets
Yahoo View Insider Transactions for IPCI - Yahoo! Finance NASDAQ View Institutional Holdings for IPCI - NASDAQ


Stock Charts

FinViz View IPCI Stock Insight & Charts - FinViz.com StockCharts View IPCI Investment Charts - StockCharts.com
BarChart View IPCI Stock Overview & Charts - BarChart Trading View View IPCI User Generated Charts - Trading View




Latest Financial News for IPCI


Intellipharmaceutics Announces Resignation of Chief Financial Officer
Posted on Monday November 05, 2018

TORONTO, ON / ACCESSWIRE / November 5, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the resignation of Andrew Patient, Chief Financial Officer, effective November 30, 2018 to pursue another opportunity. Mr. Patient has agreed to continue to offer his services to the Company through December 31, 2018 and is willing to continue thereafter on a consulting basis at the Company's discretion. Dr. Isa Odidi, Chairman, Chief Executive Officer and Co-Chief Scientist of the Company, commented "On behalf of the management team and the Board of Directors, I would like to thank Andrew for his contributions to Intellipharmaceutics, and to wish him every future success.


Intellipharmaceutics Regains Compliance with Nasdaq Minimum Shareholders' Equity Listing Requirements
Posted on Friday October 26, 2018

TORONTO, ON / ACCESSWIRE / October 26, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received a letter from the Hearings Advisor from the Nasdaq Office of General Counsel notifying the Company that it had regained compliance with Nasdaq's stockholders' equity requirement. The letter also informed the Company that the Company will remain subject to a "Panel Monitor" under Nasdaq Listing Rule 5815(d)(4)(A) until October 22, 2019.


Intellipharmaceutics Announces Closing of US $14.3 Million Underwritten Public Offering
Posted on Tuesday October 16, 2018

TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the closing of its previously announced underwritten public offering in the United States, resulting in the sale of 2,775,231 common shares, pre-funded warrants exercisable for 16,563,335 common shares, at an exercise price of US$0.01 per share (the "Pre-Funded Warrants"), and warrants exercisable for 20,000,000 common shares, at an exercise price of US$0.75 per share (the "Firm Warrants").


Intellipharmaceutics Announces Third Quarter 2018 Results
Posted on Monday October 15, 2018

TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2018. "We made great progress with respect to our development programs in the third quarter, despite challenging financial circumstances," said Dr. Isa Odidi, CEO of Intellipharmaceutics. In October 2018, we entered into an Underwriting Agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC ("H.C. Wainwright"), pursuant to which we agreed to issue and sell, in an underwritten public offering (the "October 2018 Offering"), 827,970 common shares and an aggregate of 16,563,335 pre-funded warrants ("Pre-Funded Warrants") exercisable into an aggregate of 16,563,335 common shares (the "Warrant Shares") together with common share purchase warrants to purchase up to an aggregate of 17,391,305 common shares ("Firm Warrants").


Stock Market & Investing Books

Enter a stock symbol to view the stock details.